BERLIN (EGMN) - Ofatumumab, a new monoclonal antibody that targets B cells, may eventually emerge as a first-line drug for previously untreated patients with chronic lymphocytic leukemia, said the primary U.S. investigator of the drug."A major route that pharmaceutical companies take [for Food and Drug Administration approval of a new anticancer drug] is to seek approval in a population with unmet need," and then follow with a confirmatory, phase III trial and additional studies to test the treatment...